Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Yet in practice, they produce completely different outcomes for completely different purposes, and choosing the wrong one means months of wasted effort targeting the wrong mechanism entirely
No treatment has been recommended for gamma-glutamyl transpeptidase, 5-oxoprolinase and dipeptidase deficiency
Quality, sourcing, and medical oversight matter because the gut is not an isolated organ
It is not formulated for diagnostic or therapeutic implementation
This multi-receptor activation enables: GLP-1R activation enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic signaling GIPR activation (highest potency: EC50 0.0643 nM) promotes insulin secretion and modulates lipid metabolism GCGR activation (EC50 5.79 nM) increases energy expenditure and promotes hepatic fat oxidation Combined receptor engagement produces dose-dependent reductions in body weight and improvements in glycemic control Research demonstrates that GLP3s balanced activation across three receptors produces superior metabolic effects compared to single or dual agonists, with phase 2 trials showing up to 24.2% weight reduction in 48 weeks[2]
US$ 21.35
US$ 21.40
US$ 21.13
US$ 25.29
US$ 20.84
US$ 29.84
